Artificial Intelligence
iBio Expands Immuno-Oncology Pipeline in AI Partnership with RubrYc Therapeutics
– iBio licenses a novel antibody targeting regulatory T cells –
– Company secures option to license additional antibodies developed with RubrYc’s predictive algorithms –
– iBio acquires an equity stake in RubrYc –
SAN DIEGO and BRYAN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announced that it has signed a definitive worldwide exclusive license agreement with RubrYc Therapeutics, Inc., (“RubrYc”) for RTX-003, an immunotherapy candidate targeting regulatory T cells (Tregs). The partnership also includes an option agreement for iBio to license additional antibodies built using RubrYc’s artificial intelligence (“AI”)-based antibody discovery platform.
“We are pleased to add another promising candidate to our growing oncology R&D pipeline, and especially one with such a compelling mechanism of action,” said Tom Isett, Chairman & CEO of iBio. “Designing an antibody that effectively binds CD25 without blocking the IL-2 signaling pathway is a widely recognized challenge, so the successful preclinical development of RTX-003 provides validation of RubrYc’s capabilities. Moving forward, we aim to replicate this discovery and development model by combining access to the RubrYc Discovery Platform with iBio’s proprietary Glycaneering and FastPharming Technologies to bring multiple new candidates to the clinic in a timely and cost-efficient manner.”
CD25 has emerged as a promising target in immuno-oncology because it is expressed by immunosuppressive Tregs and overexpressed in certain tumor cells. Preclinical data on RTX-003 has shown that it selectively binds and depletes Tregs in the tumor microenvironment without compromising immunostimulatory interleukin 2 (“IL2”) signaling to other T cells, thereby generating strong anti-tumor responses. These robust anti-tumor effects were observed using RTX-003 as a monotherapy, as well as in combination with checkpoint inhibitors.
The positive RTX-003 preclinical data are consistent with results from another non-IL2 blocking anti-CD25 antibody, one that is now in a Phase I clinical trial. Given the validation for this mechanism of action, iBio plans to use its development and manufacturing capabilities to advance RTX-003 to the clinic as IBIO-101, which is a version of RTX-003 produced in plants using the FastPharming System. Initiation of IND-enabling studies is expected by mid-2022.
As part of the agreements, iBio made an upfront $5.0 million payment to RubrYc, with an additional $2.5 million commitment for December 2021. In return, the Company will receive the RTX-003 commercialization rights, options for additional molecules developed using RubrYc’s predictive algorithms, and an equity stake. RubrYc is eligible to receive certain pre-specified payments upon achievement of development milestones for IBIO-101, as well as royalties on net sales of that molecule and other licensed antibodies.
Isaac J. Bright, M.D., CEO of RubrYc, commented: “This partnership creates tremendous synergy with three platform technologies that together may accelerate the rapid discovery and development of next-generation immunotherapies. We look forward to our exciting new collaboration with iBio.”
About RubrYc Therapeutics, Inc.
RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective mono and bispecific antibodies. Inspired by recent advances in molecular library synthesis, massively parallel screening and computing, RubrYc is forging a new path for information-driven discovery of therapeutic antibodies. RubrYc Therapeutics, Inc. leverages the MEMs Discovery Engine technology to rapidly identify large numbers of antibodies with unique binding properties against validated and challenging targets. RubrYc spun out of HealthTell, Inc. in 2018 to advance discovery of biotherapeutics, and to partner with top-tier pharmaceutical companies that share its mission to expand therapeutic options and improve outcomes for cancer patients. RubrYc is based in San Carlos, California. For more information, visit www.rubryc.com.
About iBio, Inc.
iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its FastPharming System® combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly develop high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services™ for advanced recombinant protein design. For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Company’s aim to replicate the discovery and development model by combining access to the RubrYc Discovery Platform with the Company’s proprietary Glycaneering TechnologiesTM and FastPharming System® to bring multiple new candidates to the clinic in a timely and cost-efficient manner, the Company’s plans to use its development and manufacturing capabilities to advance RTX-003 to the clinic as IBIO-101, initiation of IND-enabling studies expected by mid-2022, and the three platform technologies together accelerating the rapid discovery and development of next-generation immunotherapies. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to successfully bring new candidates to the clinic in a timely and cost- efficient manner, the Company’s ability to use its development and manufacturing capabilities to advance RTX-003 to the clinic, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including RTX-003, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize the Company’s product candidates for specific indications, acceptance of the Company’s product candidates in the marketplace and the successful development, marketing or sale of the Company’s products, the Company’s ability to maintain its license agreements, the continued maintenance and growth of its intellectual property portfolio, the Company’s ability to establish and maintain collaborations, the Company’s ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, the Company’s ability to retain its key employees or maintain its NYSE American listing, and the other risk factors discussed in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contacts:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]
Artificial Intelligence
Northern Data Group platform, Peak Mining, announces purchase of a second 300MW data center location in Corpus Christi, Texas
The location expands on an adjacent 300MW site, purchased in December 2023 The site comes with an ERCOT-approved interconnect of 300MWConstruction already underway, with long-lead time items secured and energization scheduled for early 2025FRANKFURT, Germany, May 24, 2024 /PRNewswire/ — Peak Mining, part of the Northern Data Group , announces the purchase of a second 300MW ERCOT-approved site in Corpus Christi, Texas. The location is adjacent to the 300MW mining facility that is already under construction. The site also provides energy in the attractive low-cost power zone of Load Zone South of the ERCOT grid, known for its abundance of renewable (wind) energy.
The investment represents a significant step forward in Northern Data Group’s investment strategy, cementing expansion plans well beyond the current 2024 financial year.
The new site enables Peak Mining to accelerate its expansion plans to become one of the largest bitcoin miners globally. The company will be deploying indoor, custom-designed, fully-integrated and liquid-cooled HPC data center systems to drastically improve deployment time and infrastructure cost, bringing Peak Mining to a leading position in the industry and preparing it for the future of HPC compute.
Saxet Infrastructure Group (“Saxet”) will act as construction manager for the design, build and energization of the substation. The Saxet team brings a strong track record of project management and deep expertise with the construction of HPC infrastructure.
Niek Beudeker, Managing Director of Northern Data Group Platform, Peak Mining, commented:
“The purchase of this second large site will significantly shorten our time to hashing and kick off one of the fastest mining expansions globally. We now have almost 700MW of sites in active development, that when fully fitted with our latest-generation hardware, could potentially provide up to 40EH of hash rate.”
Aroosh Thillainathan, Northern Data Group’s Chief Executive Officer, commented:
“This second data center location demonstrates how Northern Data Group is able to harness the power and opportunity of HPC. Sustainability has been at the core of this further expansion into the US and thanks to the center’s ERCOT approved status, we will be able to scale our operations at speed, as the demand for digital assets continues to grow.”
Steven Quisenberry, Chief Executive Officer at Saxet Infrastructure Group, commented:
We are excited to support Northern Data Group’s expansion in the ERCOT market and specifically to welcome them to the Corpus Christi area. The combination of base load industrial demand and significant renewable resources creates a unique opportunity for their portfolio. This is a terrific example of one of the largest, most advanced liquid cooled data centers in North America and we are proud to partner with Northern Data Group to bring their data center online.
Northern Data Group was advised on the transaction by Katten Muchin Rosenman LLP (Legal Counsel) and BitOoda Technologies LLC.
About Peak Mining
Peak Mining, part of the Northern Data Group, is powering the future of the blockchain network. We deliver industry-leading operating and energy efficiency in bitcoin mining through the latest hardware alongside innovative technology and infrastructure. With our mining heritage dating back to 2013, we’ve been innovating for over a decade and have been at the forefront of the industry ever since. Our high-quality infrastructure is purpose-built to power the mining network, and we’re driven to continuously find new efficiencies driving value for our investors. We’re delivering long term value in more responsible ways.
About Northern Data Group
Northern Data Group (ETR: NB2) is a leading provider of High Performance Computing (HPC) solutions to businesses and research institutions, utilizing GPU- and ASIC-based solutions. Our flexible compute power fuels innovation in our three core business platforms: Taiga Cloud, Ardent Data Centers, and Peak Mining. Through our HPC solutions, we pioneer ambitious computing innovation that drives progress in the AI, ML and Generative AI industries. Our close collaboration with industry-leading manufacturers including Gigabyte, AMD, and NVIDIA is fundamental to the acceleration of innovation across sectors including life sciences, financial services, and energy.
View original content:https://www.prnewswire.co.uk/news-releases/northern-data-group-platform-peak-mining-announces-purchase-of-a-second-300mw-data-center-location-in-corpus-christi-texas-302154571.html
Artificial Intelligence
Omnicom Media Group Expands Its Partnership with Lumen, Further Advancing Attention-Based Planning Capabilities Across Its Regions
LONDON, May 24, 2024 /PRNewswire/ — Omnicom Media Group (OMG) the media services division of leading global marketing and corporate communications holding company Omnicom Group Inc (NYSE: OMC) is expanding its market intelligence relationship with leading attention research company Lumen to now include data integration.
Under the terms of the agreement, attention data from the Lumen’s Attention Measurement Platform – which includes expected average viewing time and attentive seconds per thousand impressions – will be integrated into channel planning tools and processes within Omni, the open operating system that supports all Omnicom agencies. The addition of the Lumen attention benchmarks further advances OMG’s industry-leading attention-based planning capabilities, adding additional depth and breadth of insights to the existing attention datasets within Omni that enable attention to be leveraged as a KPI for media decisioning and creative optimization across OMG agencies OMD, PHD and Hearts & Science.
Over the past eight years, OMG has partnered with Lumen and other leading experts in attention measurement on hundreds of studies involving over 640,000 individuals worldwide, collecting nuanced attention benchmarks that offer invaluable insight into how content is consumed across various devices, channels, platforms, and formats. Activated within Omni, these datasets have enabled more precise channel selection tailored to the attention needs of individual campaigns.
“With the addition of the Lumen data, planning teams across OMG will have greater visibility into the attention value that each channel and format generates for their clients, ensuring optimal delivery of the right level of attention based on brand, brief and budget,” says OMG EMEA CEO Dan Clays.
Adds Mike Follett, CEO of Lumen, “The combination of Lumen’s attention data with OMG’s best-in-class Omni channel planning capabilities translates to a significant leap forward in leveraging attention to drive better outcomes for marketers.”
About Omnicom Media Group Omnicom Media Group (OMG), the media services division of Omnicom Group Inc. (NYSE: OMC), delivers transformational experiences for consumers, clients, and talent. Powered by the Omni marketing orchestration system, OMG connects best-in-class capabilities that enable our full-service media agencies OMD, PHD and Hearts & Science to deliver more relevant and actionable consumer experiences; more productive and proactive client experiences; and more collaborative and rewarding talent experiences for the more than 24,000 people serving the world’s leading brands in OMG agencies around the globe.
About Lumen ResearchLumen is the world’s leading attention technology company, with large-scale biometric datasets based on real-world and predictive eye-tracking technology that helps brands and agencies plan, buy and optimise media campaigns on the basis of human attention with creative, programmatic, and measurement solutions. Founded in 2013, Lumen is headquartered in London with offices in New York and LA.
View original content:https://www.prnewswire.co.uk/news-releases/omnicom-media-group-expands-its-partnership-with-lumen-further-advancing-attention-based-planning-capabilities-across-its-regions-302154915.html
Teams can eliminate container security exposures with the new enhancements in Picus’ platform for multi-cloud
SAN FRANCISCO, May 23, 2024 /PRNewswire/ — Picus Security, the Security Validation company, today announced security validation for Kubernetes. This new capability allows Security and DevOps teams to realize the benefits of containers securely by proactively measuring and optimizing the resilience of clusters. It is the latest innovative addition to the Picus Security Validation Platform, which empowers users to consistently validate their security posture and measure risk across on-premises and multi-cloud environments.
For organizations that want an agile way to deploy, run and scale applications, Kubernetes offers considerable benefits. However, security is often the biggest barrier to its adoption. The dynamic and complex nature of Kubernetes means that containers are often misconfigured due to human error. Without a hands-on approach to governance, security gaps can easily emerge over time, increasing the risk of incidents. This situation is exacerbated by the high level of expertise required to secure Kubernetes and the use of default settings which are inherently insecure. According to The State of Kubernetes Report, more than two-thirds of Kubernetes users (67%) have delayed deployments due to security concerns.*
The addition of Kubernetes validation extends the Picus platform’s existing validation capabilities, which are powered by attack simulation and GenAI. It enables organizations to proactively identify and mitigate security misconfigurations, such as weak policies and settings that could allow containers to run with insecure privileges and facilitate lateral movement. Now security teams can automatically assess the security of their workloads wherever they are located – on-premises, in containers, and also in cloud platforms including Amazon Web Services, Google Cloud Platform, and Microsoft Azure.
“Cloud security is perhaps the biggest barrier of entry for organizations that want to take advantage of container orchestration,” said Volkan Erturk, Picus CTO and Co-Founder. “Kubernetes offers incredible opportunities for DevOps teams to deploy and scale new applications, but Security teams can struggle to keep pace.
“With the Picus Security Validation Platform, security concerns won’t slow down an organization’s digital transformation journey. This new offering will allow our users to consistently measure the security of their workloads and vastly reduce the effort needed to address exposures across growing IT environments.”
Additional Information
Read the Kubernetes validation announcement blog.Register for the upcoming webinar on July 11th 2024 at 10.00 EST/ 15.00 BST: Beyond Cloud Security Posture Management: Validating Cloud Effectiveness with Attack Simulation About Picus Security
Picus Security helps security teams consistently and accurately validate their security posture. Our Security Validation Platform simulates real-world threats to evaluate the effectiveness of security controls, identify high-risk attack paths to critical assets, and optimize threat prevention and detection capabilities.
As the pioneer of Breach and Attack Simulation, we specialize in delivering the actionable insights our customers need to be threat-centric and proactive.
Picus is a Gartner® Peer Insights™ Customers’ Choice for 2024 in the BAS tools category†. The company is recognized as a leader by Frost & Sullivan^.
† Gartner, Voice of the Customer for Breach and Attack Simulation Tools, Peer Contributors, 30 January 2024 ^ Frost and Sullivan, 2022 Frost Radar™ report for the Global Breach and Attack Simulation Market
Logo: https://mma.prnewswire.com/media/2183222/4724563/Picus_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/picus-security-launches-security-validation-for-kubernetes-302154775.html
-
Uncategorized6 days agoCoca-Cola: The future is ‘AI meets human ingenuity’
-
Artificial Intelligence6 days agoMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Uncategorized6 days ago
The rise of intelligent automation as a strategic differentiator
-
Uncategorized7 days ago
Brinc Acquires Callmi – MENA’s #1 Mentorship Platform
-
Uncategorized6 days ago
AI, bias and experiments: how Women in News is tackling tech’s inbuilt stereotypes
-
Uncategorized7 days ago
From Ancient Marvels to Modern Innovations: Trip.com Spotlights Current Museum Trends for International Museum Day
-
Uncategorized6 days ago
Sainsbury’s aims to be an ‘AI-enabled grocer’ with Microsoft AI technology
-
Uncategorized6 days ago
Sony Music slams tech giants for unauthorised use of stars’ songs
